Cyclospora First Deaths: Expert Explains Why Cases Are So Difficult to Trace and What Infection Preventionists Should Know
Michigan health officials confirmed the first two deaths tied to the largest US Cyclospora outbreak on record, both in patients with significant underlying conditions worsened by cyclosporiasis and dehydration. The outbreak has now affected 45 states, with contaminated iceberg lettuce from Taylor Farms in central Mexico identified as one source across nine states. Clinical implications: Consider Cyclospora in patients presenting with prolonged, watery, non-bloody diarrhea with fatigue, especially with recent produce consumption or travel — routine stool ova-and-parasite exams may miss it, so specific PCR/antigen testing or acid-fast staining may be needed. Clinicians should have a lower threshold for aggressive oral/IV rehydration and hospitalization referral in elderly or comorbid patients, who appear at highest risk for severe outcomes. Full Access: Infection Control
Oral Step-Down, Optimal Drug, and Total Duration of Antibiotic Treatment in African Children Hospitalized with Severe Community-Acquired Pneumonia (Pedicap): A Factorial Randomized Controlled Trial
The PediCAP trial, a large factorial RCT across 1,101 children aged 2 months–6 years hospitalized with severe community-acquired pneumonia in five sub-Saharan African countries, found that stepping down from IV antibiotics to oral amoxicillin (or amoxicillin-clavulanate) after clinical improvement — following a median of just two days of IV therapy — was non-inferior to completing the WHO-standard five-day IV course, with 28-day readmission/death rates of 5.6%, 6.9%, and 6.3%, respectively. It also showed that a shorter total antibiotic course of 4–5 days performed as well as 7–8 days, and step-down patients were discharged about a day sooner. Clinical implications: This article reinforces the broader antibiotic stewardship principle relevant to urgent care: shorter, appropriately-dosed oral courses are often equally effective as longer or parenteral regimens; supporting judicious use of shortest-effective-duration oral therapy. Full Access: The Lancet
FDA Approves First OTC Acetaminophen/Naproxen Sodium Fixed-Dose Tablet
On July 24, 2026, the FDA approved Acetaminophen with Naproxen, the first fixed-dose combination product to pair acetaminophen with naproxen sodium in a single tablet, providing up to 12 hours of pain relief, indicated for pain in patients 12 years and older. Clinical implications: This gives Urgent Care clinicians a practical opioid-free, more convenient alternative for common acute pain complaints that reduces the risk of patients self-combining OTC acetaminophen and NSAIDs. Full Access: FDA
Antihistamines for Atopic Dermatitis (Eczema): Systematic Review and Network Meta-Analysis of Randomized Trials
This meta-analysis evaluated add-on oral antihistamines for atopic dermatitis and found that both first- and second-generation H1 antihistamines produce only statistically detectable, not clinically meaningful, reductions in eczema severity and itch, falling well below established minimal important differences. None of the agents reliably improved sleep disturbance or reduced flares. First-generation antihistamines increased cognitive impairment (sedation, confusion) and treatment discontinuation from adverse events, while among second-generation agents, cetirizine and levocetirizine—but not loratadine—also raised cognitive impairment risk. Clinical implications: Adding an oral antihistamine (especially a sedating first-generation agent like diphenhydramine or hydroxyzine) offers little to no meaningful symptom relief and carries real risk of sedation/cognitive side effects. Full Access: BMJ